Follow The Filings

BNTC Benitec Biopharma

Benitec Biopharma earnings company data as of 4:48 AM ET 10/23

Scheduled

2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —
FY2026 Q2 28 Sep EPS -0.27 — —
Rev — — —

Insider trades

Open-market buys and sales by BNTC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BNTC insider trades
  • $22.4M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Suvretta Capital Management, LLC Director, +3 joint filers
    Buy
    $1.9M 144,223 shares at $13.20 +8.5% to stake
    Traded Dec 23–29 Filed Dec 29, 2025
    ↗
  2. Suvretta Capital Management, LLC Director, +3 joint filers
    Buy
    $539K 46,141 shares at $11.68 +2.6% to stake
    Traded Dec 18–22 Filed Dec 22, 2025
    ↗
  3. Suvretta Capital Management, LLC Director, +3 joint filers
    Buy
    $20M 1,481,481 shares at $13.50 +438% to stake
    Traded Nov 7, 2025 Filed Nov 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 gift.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 4.01 Filing Doc
8-K 4.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
10-K/A Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
424B3 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.